Firefly Neuroscience, Inc. - SIC # 7370 -

Ticker Exchange SIC # Website Latest Ticker
AIFF Nasdaq 7370 fireflyneuro.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Firefly Neuroscience, Inc.

Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform - Jan 14th, 2025 12:45 pm
Firefly Neuroscience Closes on Financing of up to $12.4 Million - Dec 31st, 2024 2:00 pm
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman - Dec 4th, 2024 2:00 pm
Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023) - Nov 16th, 2024 1:40 pm
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - Nov 14th, 2024 10:30 pm
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event - Nov 6th, 2024 2:00 pm
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 25th, 2024 8:10 pm
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data - Oct 21st, 2024 12:30 pm
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology - Oct 16th, 2024 1:20 pm
Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder - Oct 15th, 2024 1:00 pm
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis - Sep 20th, 2024 1:00 pm
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform - Sep 10th, 2024 1:00 pm
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors - Sep 5th, 2024 1:00 pm
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11 - Aug 26th, 2024 1:00 pm
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th - Aug 22nd, 2024 1:00 pm
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders - Aug 21st, 2024 1:00 pm
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq - Aug 13th, 2024 8:06 pm
Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq - Aug 13th, 2024 1:00 pm